ArcticZymes Technologies ASA AZT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 25.90
- Day Range
- NOK 25.50–25.95
- 52-Week Range
- NOK 24.20–47.50
- Bid/Ask
- NOK 24.20 / NOK 26.00
- Market Cap
- NOK 1.32 Bil
- Volume/Avg
- 4,616 / 33,863
Key Statistics
- Price/Earnings (Normalized)
- 61.98
- Price/Sales
- 11.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments that are Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 61
- Website
- https://www.arcticzymes.com
Comparables
Valuation
|
Metric
|
AZT
|
301207
|
SCLX
|
|---|---|---|---|
Price/Earnings (Normalized) | 61.98 | 18.19 | — |
Price/Book Value | 4.25 | 2.09 | — |
Price/Sales | 11.05 | 5.76 | 2.39 |
Price/Cash Flow | 39.11 | 16.73 | — |
Price/Earnings
AZT
301207
SCLX
Financial Strength
|
Metric
|
AZT
|
301207
|
SCLX
|
|---|---|---|---|
Quick Ratio | 8.97 | — | 0.15 |
Current Ratio | 12.96 | — | 0.19 |
Interest Coverage | 34.34 | — | −106.04 |
Quick Ratio
AZT
301207
SCLX
Profitability
|
Metric
|
AZT
|
301207
|
SCLX
|
|---|---|---|---|
Return on Assets (Normalized) | 6.11% | 9.39% | −106.47% |
Return on Equity (Normalized) | 6.73% | 11.86% | — |
Return on Invested Capital (Normalized) | 4.50% | 11.24% | −1,960.39% |
Return on Assets
AZT
301207
SCLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wbnrmtwkg | Nvtt | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kdqrpxg | Bdyyqnc | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mxwgqgrv | Tflkclg | $99.2 Bil | |
MRNA
| Moderna Inc | Gvqvrrlg | Xgh | $42.7 Bil | |
ARGX
| argenx SE ADR | Vdnzyyb | Yhkwf | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Bynxjcj | Qjckz | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sdtrlszfz | Qbtlhd | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qfghsqnd | Bhjhc | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kdkqdxkctm | Fnzwlfw | $12.7 Bil | |
INCY
| Incyte Corp | Pgykbqm | Yqptwr | $11.9 Bil |